Second take on short-supply drug markups exonerates distributors

Rep. Elijah Cummings may have overstated alleged "gray market" price-gouging for drugs in short supply and done a public disservice to small distributors, according to Superior Medical Supply, one of his probe targets. In early October, Cummings cited data from a report published by group purchaser Premier health alliance showing that short-supply drug markups average 650% and have reached 4,500%. Pharmaceutical Commerce reported last week that Premier acknowledged its data showed a markup range of 29% to 729%. Plus, the comparison ignores the "market reality" that prices negotiated by group purchasers are generally 40% to 50% lower than the small distributor cost, says a statement from the National Coalition of Pharmaceutical Distributors. Letter | Story | NCPD release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.